{
    "clinical_study": {
        "@rank": "45460", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating\n      patients who have advanced kidney cancer."
        }, 
        "brief_title": "Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer", 
        "completion_date": {
            "#text": "March 2005", 
            "@type": "Actual"
        }, 
        "condition": "Kidney Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Renal Cell", 
                "Kidney Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the response rate of patients with advanced renal cell carcinoma when treated\n           with rebeccamycin analogue.\n\n        -  Assess the quantitative and qualitative toxicities associated with this drug in this\n           patient population.\n\n      OUTLINE: Patients receive rebeccamycin analogue IV over 30-60 minutes daily for 5 days.\n      Treatment continues every 21 days in the absence of disease progression or unacceptable\n      toxicity.\n\n      PROJECTED ACCRUAL: A total of 23-44 patients will be accrued for this study within 9-18\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Histologically or cytologically confirmed locally advanced unresectable, locally\n             recurrent, or metastatic renal cell carcinoma not eligible for a higher priority\n             trial\n\n          -  Measurable disease\n\n               -  Longest diameter at least 20 mm with conventional techniques or at least 10 mm\n                  with spiral CT scan\n\n          -  No nonmeasurable disease only including:\n\n               -  Bone lesions\n\n               -  Leptomeningeal disease\n\n               -  Ascites\n\n               -  Pleural/pericardial effusion\n\n               -  Lymphangitis cutis/pulmonis\n\n               -  Abdominal masses not confirmed and followed by imaging techniques\n\n               -  Cystic lesions\n\n          -  No known brain metastases\n\n               -  History of brain metastases that have been resected and/or irradiated with\n                  subsequent normal brain CT scan allowed\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 and over\n\n        Performance status:\n\n          -  ECOG 0-2 OR\n\n          -  Karnofsky 60-100%\n\n        Life expectancy:\n\n          -  Greater than 12 weeks\n\n        Hematopoietic:\n\n          -  Absolute neutrophil count at least 1,500/mm^3\n\n          -  Platelet count at least 100,000/mm^3\n\n        Hepatic:\n\n          -  Bilirubin no greater than 1.5 mg/dL\n\n          -  AST/ALT no greater than 2.5 times upper limit of normal\n\n        Renal:\n\n          -  Creatinine no greater than 1.5 mg/dL OR\n\n          -  Creatinine clearance at least 60 mL/min\n\n        Cardiovascular:\n\n          -  No symptomatic congestive heart failure, unstable angina pectoris, or cardiac\n             arrhythmia\n\n        Other:\n\n          -  Not pregnant or nursing\n\n          -  Fertile patients must use effective contraception\n\n          -  No other prior malignancy within the past 2 years except nonmelanoma skin cancer or\n             carcinoma in situ of any site\n\n          -  No history of allergic reactions attributed to compounds of similar chemical or\n             biologic composition to rebeccamycin analogue\n\n          -  No other concurrent uncontrolled illness (e.g., ongoing or active infection)\n\n          -  No concurrent psychiatric illness or social situation that would preclude study\n             compliance\n\n          -  HIV negative\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  Prior biologic therapy allowed\n\n          -  Recovered from toxic effects\n\n        Chemotherapy:\n\n          -  No prior chemotherapy\n\n        Endocrine therapy:\n\n          -  Not specified\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n          -  At least 4 weeks since prior radiotherapy and recovered\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n        Other:\n\n          -  No other concurrent investigational or commercial agents or therapies for renal cell\n             cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "April 6, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005027", 
            "org_study_id": "CDR0000067548", 
            "secondary_id": [
                "U01CA062487", 
                "P30CA022453", 
                "WSU-C-2063", 
                "NCI-T99-0113"
            ]
        }, 
        "intervention": {
            "intervention_name": "becatecarin", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "stage III renal cell cancer", 
            "stage IV renal cell cancer", 
            "recurrent renal cell cancer"
        ], 
        "lastchanged_date": "April 3, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/WSU-C-2063"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Detroit", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48201-1379"
                }, 
                "name": "Barbara Ann Karmanos Cancer Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase II Study of Rebeccamycin Analog in Renal Cell Cancer", 
        "overall_official": {
            "affiliation": "Barbara Ann Karmanos Cancer Institute", 
            "last_name": "Ulka N. Vaishampayan, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2005", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005027"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "citation": "Ibrahim D, Hussain M, LoRusso P, et al.: Rebeccamycin analog (BMY-27557-14) in renal cell cancer (RCC): preliminary results of a phase II trial. [Abstract] Proceedings of the American Society of Clinical Oncology A-2373, 2001."
        }, 
        "source": "Barbara Ann Karmanos Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Barbara Ann Karmanos Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }, 
    "geocoordinates": {
        "Barbara Ann Karmanos Cancer Institute": "42.331 -83.046"
    }
}